Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2003

View Archived Issues

AlphaVax receives biodefense grants

Phase II study evaluates Remune in HIV patients in Italy

SBIR grant will help fund development of CEL-1000 for vaccinia and smallpox infections

Nabi commences confirmatory phase III trial of StaphVAX ahead of schedule

NIAID award funds work at Progenics on prophylactic HIV vaccine

XMP-629 enters phase I trial for topical treatment of acne

SARS vaccine development at Baxter boosted by NIAID award

CO-501 enters clinical testing

Positive phase III results for Actiza

New antifungal agents presented by OGS researchers

VR1 antagonists for urinary incontinence and pain claimed by Abbott

GSK patents cover novel NK1 antagonists, their preparation and use

New CXCR3 antagonists described in Celltech R&D patent

KuDOS patent describes ATM inhibitors with potential in cancer and HIV therapy

Lilly scientists design new PPARalpha/PPARgamma modulators

Data monitoring committee recommends continuation of phase III Cubicin study

deCODE discovers gene in obesity alliance with Merck

Combination therapy with SERMs for osteopenia

Clinical evidence of teriparatide efficacy grows

Final Panzem formulations selected

AMG-162 demonstrates beneficial pharmacokinetics, activity in osteoporosis

Cinacalcet effective in preclinical and clinical studies

Inex begins submission of rolling NDA for Onco TCS

Expansion of phase III Virulizin trial

Dexanabinol receives fast track designation for traumatic brain injury

Tarceva fails to meet primary endpoint in two phase III NSCLC trials

Excellent activity demonstrated by new fluoroquinolone against multidrug-resistant staphylococci

Low-molecular-weight antiangiogenic agent effective in mouse model of brain cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...